377 related articles for article (PubMed ID: 32429580)
1. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
Parang K; El-Sayed NS; Kazeminy AJ; Tiwari RK
Molecules; 2020 May; 25(10):. PubMed ID: 32429580
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
[TBL] [Abstract][Full Text] [Related]
3. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
4. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Rescue by transcriptional inhibition.
Shilatifard A
Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
[No Abstract] [Full Text] [Related]
6. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
8. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
9. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
11. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
13. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.
Brown AJ; Won JJ; Graham RL; Dinnon KH; Sims AC; Feng JY; Cihlar T; Denison MR; Baric RS; Sheahan TP
Antiviral Res; 2019 Sep; 169():104541. PubMed ID: 31233808
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir: First Approval.
Lamb YN
Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
[TBL] [Abstract][Full Text] [Related]
19. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Thalha AMM; Lee YY; Besari A; Omar SFS
J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
[No Abstract] [Full Text] [Related]
20. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.
Pasquereau S; Nehme Z; Haidar Ahmad S; Daouad F; Van Assche J; Wallet C; Schwartz C; Rohr O; Morot-Bizot S; Herbein G
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
